Payment overview · 2025
General Payments
$666.17
43 reported records · 10 companies
Healthcare provider profile · identity verified
Paul Piezas Pena, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OVERLAND PARK, KS · NPI 1497017149
Verified facts
What the public records show
CMS Open Payments records show Paul Piezas Pena, MD received $666.17 in general payments during 2025 across 43 reported records.
Amgen Inc. accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Arexvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $159.57 | 23.9% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $138.10 | 20.7% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $114.37 | 17.2% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $76.16 | 11.4% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.71 | 7.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.75 | 6.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $25.67 | 3.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.57 | 3.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.08 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.19 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $666.17 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $138.10 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $115.28 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $115.28 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $96.68 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $91.75 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $76.16 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $62.64 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $46.35 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $44.60 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $44.29 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $25.67 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 17 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 81 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
34 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 943 | 276 |
| Losartan Potassium | Losartan Potassium | 465 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 380 | 126 |
| Omeprazole | Omeprazole | 356 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 354 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 308 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 245 | 70 |
| Metformin Hcl | Metformin Hcl | 244 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 58 |
| Trazodone Hcl | Trazodone Hcl | 201 | 67 |
| Gabapentin | Gabapentin | 191 | 64 |
| Tramadol Hcl | Tramadol Hcl | 175 | 52 |
| Famotidine | Famotidine | 174 | 62 |
| Lisinopril | Lisinopril | 170 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 138 | 32 |
| Alprazolam | Alprazolam | 137 | 37 |
| Allopurinol | Allopurinol | 136 | 39 |
| Ezetimibe | Ezetimibe | 125 | 37 |
| Simvastatin | Simvastatin | 114 | 33 |
| Spironolactone | Spironolactone | 108 | 32 |
| Glipizide Er | Glipizide | 106 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 25 |
| Sertraline Hcl | Sertraline Hcl | 100 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 27 |
| Furosemide | Furosemide | 93 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 50 |
| Finasteride | Finasteride | 89 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 27 |
| Atenolol | Atenolol | 88 | 29 |
| Irbesartan | Irbesartan | 84 | 22 |
| Eliquis | Apixaban | 81 | 23 |
| Azelastine Hcl | Azelastine Hcl | 80 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 77 | 17 |
| Carvedilol | Carvedilol | 76 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 74 | 57 |
| Potassium Chloride | Potassium Chloride | 72 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 30 |
| Chlorthalidone | Chlorthalidone | 66 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 49 |
| Repatha Sureclick | Evolocumab | 59 | suppressed |
| Methylprednisolone | Methylprednisolone | 58 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 18 |
| Montelukast Sodium | Montelukast Sodium | 55 | 19 |
| Metformin Hcl Er | Metformin Hcl | 53 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 18 |
| Temazepam | Temazepam | 52 | 12 |
| Ozempic | Semaglutide | 51 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | suppressed |
| Synthroid | Levothyroxine Sodium | 50 | 14 |
| Nystatin | Nystatin | 48 | 15 |
| Bupropion Xl | Bupropion Hcl | 45 | 15 |
| Azithromycin | Azithromycin | 44 | 37 |
| Meloxicam | Meloxicam | 44 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 23 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 42 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 40 | suppressed |
| Acyclovir | Acyclovir | 38 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Prednisone | Prednisone | 35 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 34 | 34 |
| Diazepam | Diazepam | 33 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | 14 |
| Ketoconazole | Ketoconazole | 30 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 26 |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 13 |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | 11 |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 13 |
| Ciclopirox | Ciclopirox | 23 | 12 |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 14 |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 15 | 12 |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Lorazepam | Lorazepam | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $666.17 · 43 records | Amgen Inc. | AREXVY, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, Wegovy, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error